Structured review of the patient-reported outcome instruments used in clinical trials in head and neck surgery.

The number of clinical trials that relate to patients with cancer of the head and neck is growing. Patient-reported outcomes, which are rarely the primary outcome, are now an important component, and in this structured review to identify and report the characteristics of the questionnaires that have been used in these trials, we summarise the findings reported. We searched several online databases using the key terms: head and neck oncology, head and neck surgery, reconstruction, clinical trials patient-reported outcomes, questionnaires, quality of life (QoL), validated instruments, and patients' satisfaction. We screened 1342 papers to collect information about the topic of the paper, sample size, selection criteria, main advantages and disadvantages of the patient-reported outcome used, and if it was used in conjunction with another measure. A total of 54 were eligible, and from them we identified 22 questionnaires. The primary reason for using a questionnaire was its relevance to the focus of the paper, such as xerostomia, pain, or swallowing. To allow the experience of patients to be the focus of the primary outcome in a clinical trial, we recommend that the measures used should be appropriate, reliable, valid, responsive, precise, interpretable, acceptable, and feasible. The trials used validated questionnaires, but the patient-reported outcome measures tended not to be the focus. There is merit in such measures being the primary outcomes in future trials and these should be designed around an explicit hypothesis.

[1]  C. Bradford,et al.  Development and validation of the neck dissection impairment index: a quality of life measure. , 2002, Archives of otolaryngology--head & neck surgery.

[2]  P. Fayers,et al.  Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Rogers,et al.  Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines , 2016, The Journal of Laryngology & Otology.

[4]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[5]  G. Lockwood,et al.  Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. , 2005, International journal of radiation oncology, biology, physics.

[6]  D. Jäger,et al.  Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial , 2014, BMC Cancer.

[7]  Tai-Lin Huang,et al.  Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. , 2008, International journal of radiation oncology, biology, physics.

[8]  L. Dawson,et al.  Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. , 2003, International journal of radiation oncology, biology, physics.

[9]  P. Levendag,et al.  Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer. , 2009, International journal of radiation oncology, biology, physics.

[10]  K. Courneya,et al.  Effect of exercise on upper extremity pain and dysfunction in head and neck cancer survivors , 2008, Cancer.

[11]  A. Balm,et al.  Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life , 2008, Radiation oncology.

[12]  H. Seikaly,et al.  Submandibular salivary gland transfer prevents radiation-induced xerostomia. , 2000, International journal of radiation oncology, biology, physics.

[13]  Fei Liu,et al.  A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer , 2000, Supportive Care in Cancer.

[14]  M. Parmar,et al.  Physical and psychological symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms , 1999, British Journal of Cancer.

[15]  S. Singer,et al.  Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection , 2009, Head & neck.

[16]  F. Hilgers,et al.  First‐year quality of life assessment of an intra‐arterial (RADPLAT) versus intravenous chemoradiation phase III trial , 2009, Head & neck.

[17]  E. Vokes,et al.  The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity , 1996, Cancer.

[18]  Ulrich Keilholz,et al.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.

[19]  J. de Haes,et al.  Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. , 1990, British Journal of Cancer.

[20]  I. Barillot,et al.  An international phase 3 trial in head and neck cancer: Quality of life and symptom results , 2014, Cancer.

[21]  D. Brachman,et al.  The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial , 2014, Quality of Life Research.

[22]  G. Lockwood,et al.  A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[23]  J. Wheeler,et al.  Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). , 2001, International journal of radiation oncology, biology, physics.

[24]  R. Fisher,et al.  Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Dawson,et al.  Salivary Gland Sparing and Improved Target Irradiation by Conformal and Intensity Modulated Irradiation of Head and Neck Cancer , 2003, World Journal of Surgery.

[26]  D. Rischin,et al.  Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation , 2008, Journal of medical imaging and radiation oncology.

[27]  W. Burke,et al.  A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. , 2008, Archives of otolaryngology--head & neck surgery.

[28]  Robert L. White,et al.  Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. , 2003, International journal of radiation oncology, biology, physics.

[29]  N. Husain,et al.  Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma , 2015, Cancer biology & therapy.

[30]  S. Rogers,et al.  Structured review of papers reporting specific functions in patients with cancer of the head and neck: 2006 - 2013. , 2016, The British journal of oral & maxillofacial surgery.

[31]  R. Frankowski,et al.  The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. , 2001, Archives of otolaryngology--head & neck surgery.

[32]  A. Garden,et al.  Long‐term functional and survival outcomes after induction chemotherapy and risk‐based definitive therapy for locally advanced squamous cell carcinoma of the head and neck , 2014, Head & neck.

[33]  A. Negassa,et al.  Radiofrequency ablation of advanced head and neck cancer. , 2011, Archives of otolaryngology--head & neck surgery.

[34]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[35]  C. Bradford,et al.  Head and neck cancer-specific quality of life: instrument validation. , 1997, Archives of otolaryngology--head & neck surgery.

[36]  C. Terwee,et al.  The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study , 2010, Quality of Life Research.

[37]  D. Robinson,et al.  Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[38]  G. Lockwood,et al.  Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  D. Ronis,et al.  The effect of neck dissection on quality of life after chemoradiation , 2008, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[40]  B. Noriega,et al.  A pilot study of patient quality of life during radiation therapy treatment , 1994, Quality of Life Research.

[41]  P. Ballmer,et al.  Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. , 2013, Nutrition.

[42]  L. Edgar,et al.  Comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. , 2006, The Journal of otolaryngology.

[43]  A. Garden,et al.  Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Leles,et al.  Effect of intraoral low‐level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy , 2012, Head & neck.

[45]  T. Whelan,et al.  A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[46]  F. Rivera,et al.  Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial , 2009, Expert review of anticancer therapy.

[47]  S. Kaasa,et al.  Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. , 1992, Acta oncologica.

[48]  A. Carvalho,et al.  Hearing loss and complaint in patients with head and neck cancer treated with radiotherapy. , 2010, Archives of otolaryngology--head & neck surgery.

[49]  F. Hirsch,et al.  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Jan-Jakob Sonke,et al.  Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer , 2013, BMC Cancer.

[51]  S. Rogers,et al.  A double blind randomised trial of IIb or not IIb neck dissections on electromyography, clinical examination, and questionnaire-based outcomes: a feasibility study. , 2012, The British journal of oral & maxillofacial surgery.

[52]  E. Vokes,et al.  High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Cella,et al.  A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores , 2007, Quality of Life Research.

[54]  I. M. Ventry,et al.  The Hearing Handicap Inventory for the Elderly: a New Tool , 1982, Ear and hearing.

[55]  A. Bottomley,et al.  Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323) , 2010, British Journal of Cancer.

[56]  J. Hanson,et al.  Correlation Between Saliva Production and Quality of Life Measurements in Head and Neck Cancer Patients Treated With Intensity-Modulated Radiotherapy , 2007, American journal of clinical oncology.

[57]  C. V. van Hasselt,et al.  Mode of treatment affects quality of life in head and neck cancer survivors: Implications for holistic care , 2010, Acta oto-laryngologica.

[58]  I. Helenowski,et al.  Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: A pilot study , 2015, Head & neck.

[59]  L. Peters,et al.  Prospective trial to evaluate staged neck dissection or elective neck radiotherapy in patients with CT‐staged T1‐2 N0 squamous cell carcinoma of the oral tongue , 2009, Head & neck.

[60]  L. Eapen,et al.  The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Dobson,et al.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.

[62]  S. Rogers,et al.  How will I be after my operation for oral cancer? , 2015, The British journal of oral & maxillofacial surgery.

[63]  C. McConkey,et al.  PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. , 2016, The New England journal of medicine.

[64]  K. Olivier,et al.  Xerostomia in Long-term Survivors of Aggressive Non-Hodgkin's Lymphoma of Waldeyer's Ring: A Potential Role for Parotid-Sparing Techniques? , 2009, American journal of clinical oncology.

[65]  P. Maguire,et al.  Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[66]  D. Kuik,et al.  Perioperative enteral nutrition and quality of life of severely malnourished head and neck cancer patients: a randomized clinical trial. , 2000, Clinical nutrition.

[67]  C. Bokemeyer,et al.  Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire , 2022 .

[68]  N. Sanfilippo,et al.  Effects of exercise on swallowing and tongue strength in patients with oral and oropharyngeal cancer treated with primary radiotherapy with or without chemotherapy. , 2014, International journal of oral and maxillofacial surgery.

[69]  A. Bezjak,et al.  Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis , 2005, Head & neck.

[70]  M. Sullivan,et al.  Quality-of-Life Effects of Psychosocial Intervention in Patients with Head and Neck Cancer , 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[71]  J. Machiels,et al.  Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy , 2014, BMC Cancer.

[72]  E. Weymuller,et al.  Assessment of quality of life in head and neck cancer patients , 1993, Head & neck.

[73]  J. Mountz,et al.  Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. , 2009, International journal of radiation oncology, biology, physics.

[74]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[75]  M. List,et al.  A performance status scale for head and neck cancer patients , 1990, Cancer.

[76]  S. Rogers,et al.  Where do patients treated for oral cancer die? A 20-year cohort study 1992-2011. , 2015, The British journal of oral & maxillofacial surgery.

[77]  R. Snaith,et al.  The Hospital Anxiety and Depression Scale , 1983 .

[78]  S. Soong,et al.  A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. , 1997, American journal of clinical oncology.